Taltz (ixekizumab) is FDA-approved for four conditions across dermatology and rheumatology, and it has beaten two of its main competitors in head-to-head clinical trials. It's also one of the specialty medications our appeals team sees denied most often — largely because another drug in the same IL-17A class reached insurers' covered drug lists first.

That drug is Cosentyx, approved in January 2015, fourteen months before Taltz. Most insurers treat the two as interchangeable, listing Cosentyx as the preferred option and requiring patients to try it before they'll consider Taltz. The clinical reality is more nuanced. These are distinct molecules with different dosing schedules, different head-to-head profiles, and documented cases of patients responding to one after the other didn't work well enough. Your appeal letter needs to make that distinction clearly, or it gets filed in the denial pile.

This guide walks through a proven appeal letter structure section by section, explains how to customize each part for your specific Taltz denial, and covers what to do if the first response comes back unfavorable.

If you'd prefer not to build an appeal from scratch, Claimable generates fully customized Taltz appeals backed by a purpose-built database of clinical studies, insurer policies and legal standards, then submits them directly to your insurer on your behalf.

Start Here: Identify Your Denial Type

Before writing anything, find the exact denial reason on your letter. The entire strategy changes depending on which barrier you're facing.

Taltz treats four distinct conditions — moderate-to-severe plaque psoriasis in adults and children aged 6 and older, active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation — and each carries its own step therapy requirements and supporting clinical evidence. A psoriasis appeal built around PASI scores (a measure of psoriasis severity) won't help if the denial is for psoriatic arthritis and the insurer's objection is about joint disease documentation.

If the denial traces back to a correctable issue — a missing TB screening, an outdated severity assessment, or a wrong diagnosis code — you may not need a formal appeal at all. A resubmission with the missing documentation can sometimes resolve it faster.

Taltz Appeal Letter: What to Include, Plus a Customizable Template

We've created a free, customizable appeal letter template you can use as a starting point for your Taltz appeal:

Download the free appeal letter template →

Each section of a strong Taltz appeal serves a specific function. Here's what to include and why.

Section 1: Identifying Information, Claim Details, and Denial Reference

Start with a header block that identifies you, your insurer's appeals department, and the specific claim at issue. The opening paragraph should name the medication, the prescribing physician, your diagnosis, and the insurer's stated denial reason, quoted directly from the letter. Reproducing their exact language matters. Everything that follows is a targeted response to that specific rationale.

If a gap in treatment poses a medical risk — disease progression, worsening joint damage, or your body losing its response to the medication — this is also where you request an expedited review. Plans must decide expedited appeals within 72 hours.

Note your appeal deadline immediately. Federal law guarantees you at least 180 days from the date you receive your denial notice to file an internal appeal, and plans can give you longer but never less. Medicare and Medicaid run on their own schedules — Medicare Advantage, for example, generally gives you 60 days from when you receive the notice (often published as 65 days from the notice date to allow for mailing). Your exact deadline is printed on your denial letter. Mark your calendar the day it arrives and file as early as you can.

Section 2: Your Diagnosis and Its Impact on Your Life

This section establishes your clinical profile and makes the human cost of the denial concrete. Include your diagnosis with ICD-10 codes if available, any other conditions you have, and a specific description of how your condition affects daily life.

For Taltz, the indication your prescriber documented shapes the entire appeal strategy.

For plaque psoriasis, document disease severity using PASI scores, body surface area involvement, and plaque location. Face, palms, scalp and genital psoriasis carry extra weight because they directly affect daily life. For psoriatic arthritis, center the appeal on tender and swollen joint counts, functional limitations, and the risk of irreversible joint damage. For ankylosing spondylitis or non-radiographic axial spondyloarthritis, document BASDAI scores (a disease activity questionnaire), morning stiffness duration, imaging findings, and the impact on mobility. A reviewer who sees concrete severity data reads the clinical sections differently than one who sees vague references.

Section 3: Prior Treatments and Their Outcomes

This section demonstrates that you've already done what the plan requires, or that there's a documented clinical reason those requirements don't apply to you. Present prior treatments in a clear table.

Specific dates, drug names and documented outcomes are what turn a general claim into evidence the insurer is required to address.

Two details that frequently get overlooked. First, “failure” encompasses intolerable side effects, medical reasons you can't safely take the drug, and results that didn't reach a meaningful level of improvement, in addition to complete non-response. Second, if you're currently on Taltz and responding well, the continuity of care argument — that switching would reverse clinical progress and risk flare or loss of response — belongs here as well.

Section 4: Why Taltz Is Medically Necessary

This section connects your physician's clinical judgment, your treatment history, and how your condition is trending into a single argument. It should explain why Taltz specifically, as distinct from the broader IL-17 inhibitor class, is the appropriate medication, and what happens without it.

Medical necessity is the standard most denials ultimately turn on. Explain what happens without Taltz: disease progression, irreversible joint damage, or compounding loss of function depending on your diagnosis. If your prescriber has written a letter of medical necessity, this section reinforces that clinical reasoning with your own perspective.

One detail for patients already on Taltz that's easy to miss: use your baseline disease severity from before starting treatment, not your current scores. Insurers have denied coverage based on improved numbers, penalizing patients for responding to the medication. Your pre-treatment clinical picture is what establishes the need.

Section 5: Clinical Evidence Supporting Taltz

This section does the heaviest lifting, and it’s where most generic appeal letters miss. Cite specific clinical trials, match each to your indication, and connect the data to the insurer’s stated reason for denial.

Match the trial evidence to your indication. Taltz has been studied across all four of its approved conditions, and the trials that support a plaque psoriasis claim are not the ones that support a psoriatic arthritis or axial spondyloarthritis claim. Citing a skin study for a joint-disease denial misses the point. Use the trials that fit your diagnosis, and take the response rates and any comparator data straight from the published trial rather than from memory or a summary.

If your denial is specifically a “try Cosentyx first” denial, head-to-head evidence is your most important tool — and precision matters more than enthusiasm, because a plan’s medical director will check the details. State each result exactly as the trial reported it, including the later timepoints where two drugs may converge. An appeal that overstates a result gives the reviewer a reason to distrust everything else in the letter; one that states the data precisely and then explains why your clinical profile favors Taltz is much harder to dismiss.

Document why, given your clinical profile, the insurer’s preferred agent is not the right choice: a documented inadequate response to Cosentyx, a specific dosing consideration, or head-to-head data relevant to your disease characteristics.

A serious caution: never cite a study you haven’t verified. General-purpose AI tools routinely generate fabricated clinical references. A single invented citation gives the reviewer a clean justification to dismiss your entire appeal.

Section 6: The Denial Doesn't Align With Your Insurer's Own Criteria

Insurers publish their Taltz coverage policies, and those documents are publicly available. Pull the relevant policy, identify each criterion, and show point by point that you meet them.

The effect is that the insurer has to address its own written rules. If the policy requires documented failure of a conventional systemic and your records show six months on methotrexate with liver toxicity, show the match. If it requires TNF inhibitor failure and you've tried and failed two, list them against the criteria.

For patients denied because the plan prefers Cosentyx, this section is where you demonstrate that you've already met the plan's requirements for trying preferred alternatives, or that clinical factors make the preferred agent inappropriate for your case.

Section 7: Applicable State and Federal Law

Legal citations move your appeal from a request to a demand. The specific protections available depend on your plan type and your state, but they often include the Affordable Care Act's guaranteed rights to internal appeal and independent external review, state step therapy override laws, and ERISA protections for employer-sponsored plans.

Most states have now passed some form of step therapy protection — trackers maintained by patient advocacy groups put the count in the high 20s to high 30s depending on how strictly “reform” is defined. Where such a law applies, it typically lets patients bypass a required step when they've already tried and failed comparable drugs or when the required step would cause irreversible harm.

One critical limit: state step therapy laws generally do not apply to self-funded employer plans, which cover most people with job-based insurance. Check whether your coverage is fully insured or self-funded before building an argument on a state protection.

Section 8: Request for Review and Approval

Close with a formal, specific request. Ask the insurer to approve coverage for Taltz, override the cited denial barrier, and if the situation is time-sensitive, process the appeal on an expedited basis. Ask for written confirmation of the decision. If the appeal is denied, request the complete claim file so you can see every document the reviewer considered and identify any gaps for the next level of review.

Section 9: Supporting Documentation

List everything you're including: the physician's letter of medical necessity, medical records documenting your diagnosis and treatment history, relevant lab results including TB screening, disease severity assessments, the clinical studies cited in the letter, the original denial letter, and any prior appeal decisions. Nothing should require the reviewer to go searching.

Section 10: Citations and References

End with a full reference list of every clinical trial, guideline, insurer policy and statute cited. This doubles as your own quality check. If you can't produce a clean, verifiable citation for a claim, that claim should not be in the letter.

An Alternative Approach: Use Claimable

The template above provides the architecture of a strong appeal. But the sections that determine whether it succeeds — clinical evidence, policy analysis, legal citations — are also the ones that require hours of targeted research and where errors weaken your case.

Claimable does this work for you. You answer a few questions about your Taltz denial and medical history. We build a fully customized appeal using our database of clinical studies, insurer policies and legal standards — real studies, real laws and real policy data, not a general-purpose chatbot guessing at citations. The appeal includes your personal narrative, clinical evidence matched to your condition and denial type, and a policy and legal analysis targeting your insurer's reasoning. We submit it directly to your insurer, and we guide you through escalation if it's needed.

Over 80% of Claimable appeals succeed in established conditions, with most resolved in 10 days or less. Appealing costs $39.95 plus shipping — no success fees, no hidden charges.

Start your Taltz appeal with Claimable →

Common Mistakes That Get Taltz Appeals Denied

Treating the Preferred Cosentyx Denial as a Simple Swap Request

When a plan prefers Cosentyx and you're appealing for Taltz, the instinct is to argue that both drugs are essentially the same. That approach backfires. If they're the same, the insurer has no reason to approve the non-preferred one. Your appeal needs to document why Taltz is clinically distinct for your situation, supported by head-to-head data and your individual treatment history.

Ignoring the IBD Warning When It's Relevant

Taltz carries a Warning and Precaution — not a boxed warning — for inflammatory bowel disease. If you also have IBD or a history of it, your appeal needs to address this proactively. If your prescriber chose Taltz because your IBD is inactive and clinically monitored, document that reasoning.

Get the incidence right, because it varies by condition and a blanket “under 1%” is wrong for some patients. In adult psoriasis trials, Crohn's disease occurred in 0.1% of Taltz patients and ulcerative colitis in 0.2%. In pediatric psoriasis, Crohn's was 0.9%. In ankylosing spondylitis trials the rates were 1.0% and 0.5% — so if you're appealing for AS or non-radiographic axial spondyloarthritis, use the AS figures. Your prescriber should monitor for new or worsening symptoms, and Taltz should be stopped if IBD develops.

Submitting the Same Evidence for Different Indications

A psoriasis appeal built on PASI scores won't move a reviewer evaluating a psoriatic arthritis denial. Match your evidence to your diagnosis. If you have overlapping conditions such as psoriasis and PsA, document both and cite the SPIRIT-H2H combined skin-and-joint endpoint — while being accurate that the advantage over Humira came primarily from the skin component.

Citing Fabricated Studies or Incorrect Legal References

General-purpose AI tools generate convincing-looking clinical citations that don't exist. A reviewer who catches one fabricated source has every reason to treat the entire submission as unreliable. Verify every reference before it goes near your insurer. Claimable runs on a purpose-built database of real, verified sources for exactly this reason.

Missing the Filing Deadline

Deadlines are printed on your denial letter and they are absolute. Federal law gives you at least 180 days from receiving your denial for a commercial plan internal appeal; Medicare Advantage runs on 65 calendar days from the notice date. Missing the window eliminates your right to appeal entirely. Mark the deadline the day the letter arrives.

Don't Navigate This Alone If You Don't Have To

You have the legal right to appeal, the clinical evidence to support it, and a process designed to give you multiple chances to make your case.

After you exhaust internal appeals, you have the right to an independent external review — file within four months of your final internal denial. A standard review is decided within 45 days; an urgent one within 72 hours. And if the reviewer overturns the denial, your plan is required by law to pay, and must do so without delay even if it intends to challenge the decision in court.

If you'd rather not spend hours verifying clinical studies and tracking down insurer policies, Claimable handles the research-intensive work and submits on your behalf.

Download the free appeal letter template → or start your Taltz appeal with Claimable →

FAQs

Why was my Taltz denied when my doctor prescribed it?
Taltz requires prior authorization from virtually every insurer. PA criteria typically require you to try other drugs first (like a TNF inhibitor or Cosentyx), show that your disease is severe enough, and fill your prescription through a specialty pharmacy. Your doctor made the clinical decision. The insurer is applying its own utilization rules on top.

Can I appeal a Taltz denial myself?
Yes. Patient appeals run on a separate legal track from your doctor's clinical appeal, with guaranteed response timelines, the right to external review, and multiple levels of internal appeal. Your appeal and your doctor's work on parallel tracks and strengthen each other.

My insurer wants me to try Cosentyx instead of Taltz. Are they interchangeable?
No. Although both are IL-17A inhibitors, Taltz and Cosentyx are distinct medications with different molecular structures, different dosing schedules, and different clinical trial profiles. Patients who don't respond well enough to one IL-17A inhibitor may respond to the other. If your insurer is treating them as interchangeable, your appeal should document the clinical rationale for Taltz specifically.

Is there a generic or biosimilar version of Taltz?
No. There is no FDA-approved biosimilar or generic version of Taltz in the United States — FDA's biosimilar product list contains no ixekizumab entry. Taltz was licensed in March 2016, which gives it 12 years of reference-product exclusivity through March 2028, with additional patent protection beyond that. By contrast, Stelara now has several approved biosimilars, which is often exactly why a plan will push you toward it. Taltz is dispensed through specialty pharmacies rather than retail pharmacies; more than 150 specialty pharmacies can fill it.

How much does Taltz cost without insurance?
Taltz's list price is $7,261.51 per 80 mg autoinjector or prefilled syringe. Because the loading dose is two injections and maintenance is one injection every four weeks, annual list-price cost runs roughly $94,000 at steady state, and about $109,000 to $131,000 in the first year depending on the indication — psoriasis costs more in year one because of the twice-monthly induction phase. List price is not what most insured patients pay, but it is the number that drives your plan's prior-authorization and tier decisions.

Eli Lilly's Taltz Savings Card can bring your cost down to $5 per month if you have commercial insurance that covers Taltz, or $25 per month if your commercial plan doesn't cover it — up to 3 pens per 28-day supply, with a maximum benefit of $10,600 per calendar year. You are not eligible if you have any government coverage: Medicare, Medicaid, TRICARE, VA, DoD, or a state pharmaceutical assistance program. Separately, the Lilly Cares Foundation may provide Taltz at no cost if your household income is at or below 500% of the federal poverty level (about $79,800 for an individual or $165,000 for a family of four in 2026) and you are not enrolled in Medicaid, the full low-income subsidy, or VA benefits.

What's the difference between Taltz dosing for psoriasis vs. psoriatic arthritis or AS?
For adult plaque psoriasis, Taltz starts with 160 mg at week 0 — given as two 80 mg injections, which surprises a lot of patients — then 80 mg every two weeks through week 12, then 80 mg every four weeks. For psoriatic arthritis and ankylosing spondylitis, it's 160 mg at week 0, then 80 mg every four weeks. For non-radiographic axial spondyloarthritis, there's no loading dose: 80 mg every four weeks from the start. Patients with psoriatic arthritis and coexistent moderate-to-severe plaque psoriasis follow the psoriasis schedule. Pediatric psoriasis dosing is weight-based.

Is it worth appealing a Taltz denial?
Almost always. Taltz is typically prescribed when the clinical picture calls for an IL-17A inhibitor, and for many patients that means other treatments have already been tried or are contraindicated. Untreated psoriatic disease causes irreversible joint damage, and treatment gaps with biologics risk flares and loss of response. In ankylosing spondylitis specifically, long-standing inflammation can cause new bone to form between vertebrae, and in some people the spine's joints eventually fuse — the change doctors see on X-ray as “bamboo spine.” That develops over years and does not happen to everyone; severe disability is relatively uncommon. In non-radiographic axial spondyloarthritis there is no visible joint damage on X-ray by definition, and only some patients go on to develop the radiographic form. Controlling inflammation early is one reason treatment matters.

The appeals process exists for situations where a formulary decision doesn't reflect your clinical reality. Your doctor prescribed Taltz because the evidence supports it. The appeal forces the insurer to respond to that evidence on the record.

Claimable's physician-led team has helped patients recover over $30 million in care access by fighting insurance denials. We're SOC 2 Type II certified and HIPAA compliant. Learn more about how Claimable works →

Insurer coverage policy details in this guide were verified in August 2026. Plan criteria are typically revised at least annually — check your own plan's current policy document before filing.